Targeted Alpha-Therapy Market Report 2026

The targeted alpha-therapy market size has grown rapidly in recent years. It will grow from $1.03 billion in 2025 to $1.2 billion in 2026 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to advances in nuclear medicine research, increasing unmet needs in advanced cancers, expansion of radiopharmaceutical clinical trials, availability of medical isotopes, growth in targeted radiation therapy adoption.

The targeted alpha-therapy market size is expected to see rapid growth in the next few years. It will grow to $2.25 billion in 2030 at a compound annual growth rate (CAGR) of 17%. The growth in the forecast period can be attributed to increasing investment in isotope manufacturing infrastructure, rising adoption of personalized radiotherapy, expansion of targeted alpha therapies into new indications, growing regulatory support for radiopharmaceuticals, increasing collaboration between nuclear and oncology specialists. Major trends in the forecast period include increasing development of alpha-emitting radiopharmaceuticals, rising use of targeted radioligand therapies, growing focus on precision radiation delivery, expansion of isotope production capabilities, enhanced integration of targeting molecules.

The increasing emphasis on precision medicine is expected to drive the growth of the targeted alpha-therapy market in the coming years. Precision medicine is a healthcare approach that tailors prevention, diagnosis, and treatment according to an individual’s genetic makeup, lifestyle, and environment to achieve more effective outcomes. The adoption of precision medicine is rising due to the expanding availability of genetic testing, which allows for more accurate diagnoses and targeted therapies with better patient results. Targeted alpha-therapy supports precision medicine by delivering highly potent alpha-emitting isotopes directly to cancer cells, providing personalized and precise treatment while reducing harm to healthy tissues. For example, in March 2024, the American Pharmaceutical Review, a US-based journal, reported that global spending on precision medicine treatments was nearly $32 billion in 2022 and is expected to surpass $124 billion by 2027. Consequently, the growing emphasis on precision medicine is fueling the expansion of the targeted alpha-therapy market.

Major companies operating in the targeted alpha-therapy market are concentrating on developing innovative approaches such as peptide receptor radionuclide therapy to enhance the efficacy of targeted cancer treatments, reduce off-target effects, and improve patient outcomes. Peptide receptor radionuclide therapy (PRRT) is a targeted cancer treatment that delivers radioactive isotopes directly to tumor cells by attaching them to peptides that specifically bind to receptors overexpressed on cancer cells, thereby limiting damage to healthy tissue. For example, in February 2024, RadioMedix Inc., a US-based biotechnology company, collaborated with Orano Med, a US-based pharmaceutical company, and received FDA breakthrough device designation for the first targeted alpha therapy, AlphaMedix (lead-212-Dotamtate), aimed at treating neuroendocrine tumors. It is designed to treat advanced gastroenteropancreatic neuroendocrine tumors by delivering highly potent alpha radiation directly to cancer cells while sparing healthy tissue. Its primary advantage lies in the high energy and short path length of alpha particles, which induce lethal DNA damage to tumor cells with minimal toxicity. This therapy provides a promising option for patients who are treatment-naïve or have limited response to current beta-emitter therapies, aiming to improve efficacy and safety in hard-to-treat neuroendocrine tumors.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to enhance cancer treatment and patient outcomes by developing more precise, targeted next-generation radioconjugate therapies to replace traditional chemotherapy and radiotherapy. Fusion Pharmaceuticals Inc. is a Canada-based biotech company specializing in targeted alpha-therapy.

Major companies operating in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.

North America was the largest region in the targeted alpha-therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the targeted alpha-therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the targeted alpha-therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the targeted alpha-therapy market by increasing costs of imported radioisotopes, nuclear production equipment, shielding materials, and precision delivery systems. North America and Europe are most affected due to dependence on specialized isotope supply chains, while Asia-Pacific faces higher costs in isotope production and export logistics. These tariffs are increasing treatment development costs and limiting isotope availability timelines. However, they are also encouraging domestic isotope production, regional nuclear infrastructure investment, and long-term supply chain stabilization for alpha-therapy development.

The targeted alpha-therapy market research report is one of a series of new reports that provides targeted alpha-therapy market statistics, including targeted alpha-therapy industry global market size, regional shares, competitors with a targeted alpha-therapy market share, detailed targeted alpha-therapy market segments, market trends and opportunities, and any further data you may need to thrive in the targeted alpha-therapy industry. This targeted alpha-therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Targeted alpha-therapy (TAT) is a type of radiation treatment that administers highly potent alpha-particle-emitting isotopes directly to cancer cells or diseased tissues. The therapy employs targeting molecules, such as antibodies, peptides, or small molecules, which bind specifically to cancer cell markers, enabling the alpha particles to induce lethal double-strand DNA breaks in nearby cells while reducing damage to surrounding healthy tissue.

The main isotope types of targeted alpha therapy include actinium-225, radium-223, lead-212, bismuth-213, and others. Actinium-225 is a highly potent alpha-emitting radioisotope commonly used in targeted therapies because of its suitable half-life and decay characteristics. This therapy is utilized for conditions such as prostate cancer, bone metastases, pancreatic cancer, and others, with end-users including hospitals, cancer research institutes, specialty clinics, lymphoma centers, and others.

The targeted alpha-therapy market consists of sales of neptunium-225 thorium-227 and astatine-211. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.